Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Interest & Investment Income: 2009-2025

Historic Interest & Investment Income for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to $500,000.

  • Myriad Genetics' Interest & Investment Income rose 25.00% to $500,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 38.10%. This contributed to the annual value of $1.7 million for FY2024, which is 32.00% down from last year.
  • As of Q3 2025, Myriad Genetics' Interest & Investment Income stood at $500,000, which was up 150.00% from $200,000 recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Interest & Investment Income ranged from a high of $1.1 million in Q3 2022 and a low of $100,000 during Q4 2021.
  • Its 3-year average for Interest & Investment Income is $472,727, with a median of $500,000 in 2025.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first slumped by 85.71% in 2021, then spiked by 900.00% in 2022.
  • Quarterly analysis of 5 years shows Myriad Genetics' Interest & Investment Income stood at $100,000 in 2021, then spiked by 900.00% to $1.0 million in 2022, then crashed by 30.00% to $700,000 in 2023, then slumped by 57.14% to $300,000 in 2024, then climbed by 25.00% to $500,000 in 2025.
  • Its last three reported values are $500,000 in Q3 2025, $200,000 for Q2 2025, and $300,000 during Q1 2025.